Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
A forum for researchers, students and applicants in the field of cyclodextrin technology
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
Over the last two decades organocatalysis has become an attractive synthetic tool in asymmetric catalysis. However, the increasing demand for
Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Volume One: Types and Triggers discusses, in detail, the recent trends in
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
The application of cyclodextrins as excipients is wellspread, common knowledge worldwide. Their application as APIs is getting huge publicity, developments
Mimicking the host–guest (e.g. enzyme–substrate) interaction in the nature of a temperature-controlled stepwise release and capture of cyclodextrin was achieved
ScienceDaily reported on the effect of cyclodextrins as parts of synthetic receptors on the aggregation of proteins, recently published by